arrow
K

Kasmintan A. Schrader

british columbia cancer agency
H指数:37
被引数:5,993

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

“Where do I go from here?” Navigating a lifelong road without a map: the care experiences of hereditary cancer patients

“从这里我该去往何方?”:在没有地图的情况下导航一生之路——遗传性癌症患者护理经历

2026-03-030
PRE
Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium

遗传性癌症的非侵入性筛查: 一项随机对照试验,用于在CHARM联盟中测试基于游离DNA的早期检测

2026-01-290
OA
Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdens

机会性筛查对广泛相关的临床二级发现的实验室效益与负担

2025-10-140
OAAI
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Long-read sequencing of an advanced cancer cohort resolves rearrangements, unravels haplotypes, and reveals methylation landscapes
2024-11-011
OAAI
Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers
2024-05-163
OAAI
The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals
2024-04-011
OA
I just wanted more: Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screening
2023-10-111
OA
A model for the return and referral of all clinically significant secondary findings of genomic sequencing
2023-05-224
PRE
Defining the heterogeneity of unbalanced structural variation underlying breast cancer susceptibility by nanopore genome sequencing
2023-02-166
OAAI
Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines

通过CDH1-specific种系变异管理优化临床护理: 改善临床断言和更新管理指南

2022-12-0715
OA
Whole-genome and transcriptome analysis enhances precision cancer treatment options

全基因组和转录组分析增强了精确的癌症治疗选择

2022-09-0146
OA
A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings
2022-06-232
PRE